The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Open accessAbstract
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, achieved an approximately 50% response and improved survival among metastatic melanoma patients with the BRAF V600E mutation [97].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [97]
In the citing paper
“Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [116, 117] from ESMO-MCBS 3 based on PFS to 4, based on OS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Flagged first, then by citations
Research works printed but not linked: 1
- Kumar R, 2003, Clin Cancer Res, 9, 3362
Cited by
Sorted by citations
Items 801–900 of 1,053
Hernandez, B., Adissu, H. A., Wei, B., Michael, H., Merlino, G. T., & Simpson, R. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020394 · Cited by 124
Mastio, J., Condamine, T., Dominguez, G., Kossenkov, A. V., Donthireddy, L., Veglia, F., Lin, C., Wang, F., Fu, S., Zhou, J., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181952 · Cited by 115
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
Griewank, K., Murali, R., Schilling, B., Scholz, S. L., Sucker, A., Song, M., Süßkind, D., Grabellus, F., Zimmer, L., Hillen, U., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.312 · Cited by 124
Self-citationRelevance of randomised controlled trials in oncology
Tannock, I. F., Amir, E., Booth, C. M., Niraula, S., Ocaña, A., Šeruga, B., Templeton, A. J., & Vera-Badillo, F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30572-1 · Cited by 121
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 118
Niu, J., Chu, Y., Huang, Y., Chong, Y.-S., Jiang, Z., Mao, Z., Peng, L., & Gao, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b16378 · Cited by 120
Cellular origin of glioblastoma and its implication in precision therapy
Yao, M., Li, S., Wu, X., Diao, S., Zhang, G., He, H., Bian, L., & Lu, Y. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.159 · Cited by 94
Dwane, L., Behan, F. M., Gonçalves, E., Lightfoot, H. W., Yang, W., van der Meer, D. J., Shepherd, R., Pignatelli, M., Iorio, F., & Garnett, M. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa882 · Cited by 119
Protein kinases: drug targets for immunological disorders
Castelo‐Soccio, L. A., Kim, H., Gadina, M., Schwartzberg, P. L., Laurence, A. D. J., & O’Shea, J. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00877-7 · Cited by 128
BRAF Mutations in Metanephric Adenoma of the Kidney
Choueiri, T. K., Cheville, J. C., Palescandolo, E., Fay, A. P., Kantoff, P. W., Atkins, M. B., McKenney, J. K., Brown, V. E., Lampron, M. E., Zhou, M., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.051 · Cited by 121
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Callahan, M. K., Masters, G. R., Pratilas, C. A., Ariyan, C. E., Katz, J. B., Kitano, S., Russell, V., Gordon, R. A., Vyas, S., Yuan, J. D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0160 · Cited by 116
Characterising the phenotypic evolution of circulating tumour cells during treatment
Tsao, S. C., Wang, J., Wang, Y., Behren, A., Cebon, J. S., & Trau, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03725-8 · Cited by 119
Advanced nanomedicine approaches applied for treatment of skin carcinoma
Kaur, H., & Kesharwani, P. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.003 · Cited by 120
Tasdogan, A., Sullivan, R. J., Katalinic, A., Lebbé, C., Whitaker, D., Puig, S., van de Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00603-8 · Cited by 143
Self-citationVerreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Ocular Adverse Events Associated with Mek Inhibitors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117
ToBRAFor Not toBRAF: Is That Even a Question Anymore?
Horbinski, C. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318279f3db · Cited by 118
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
Carlino, M. S., Todd, J. R., Gowrishankar, K., Mijatov, B., Pupo, G. M., Fung, C., Snoyman, S., Hersey, P., Long, G. V., Kefford, R. F., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.003 · Cited by 120
Data Set for Pathology Reporting of Cutaneous Invasive Melanoma
Scolyer, R. A., Judge, M. J., Evans, A. T., Frishberg, D. P., Prieto, V. G., Thompson, J. F., Trotter, M. J., WALSH, M. Y., Walsh, N. M. G., & Ellis, D. W. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31829d7f35 · Cited by 119
Sinha, R., Edmonds, K., Newton‐Bishop, J., Gore, M. E., Larkin, J., & Fearfield, L. A. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12010 · Cited by 116
Self-citationClinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
Sakaizawa, K., Ashida, A., Uchiyama, A., Ito, T., Fujisawa, Y., Ogata, D., Matsushita, S., Fujii, K., Fukushima, S., Shibayama, Y., et al. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.07.012 · Cited by 120
Scheerens, H., Malong, A., Bassett, K., Boyd, Z. S., Gupta, V., Harris, J. M., Mesick, C. P., Simnett, S., Stevens, H., Gilbert, H., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12455 · Cited by 120
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Audrito, V., Serra, S., Stingi, A., Orso, F., Gaudino, F., Bologna, C., Neri, F., Garaffo, G., Nassini, R., Baroni, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15213 · Cited by 118
Gatalica, Z., Xiu, J., Swensen, J. J., & Vranić, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.021 · Cited by 118
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Wu, R.-Y., Kong, P., Xia, L.-P., Huang, Y., Li, Z., Tang, Y.-Y., Chen, Y.-H., Li, X., Senthilkumar, R., Zhang, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2840 · Cited by 116
Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker
Sharma, A., & Johnson, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29153 · Cited by 122
Lipid Metabolism and Resistance to Anticancer Treatment
Germain, N., Dhayer, M., Boileau, M., Fovez, Q., Kluza, J., & Marchetti, P. (2020) · Biology · doi:10.3390/biology9120474 · Cited by 115
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 133
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas
Liu, F., Cao, J., Wu, J., Sullivan, K., Shen, J. L., Ryu, B., Xu, Z., Wei, W., & Cui, R. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.32 · Cited by 126
Routhier, C. A., Mochel, M. C., Lynch, K. D., Dias-Santagata, D. C., Louis, D. N., & Hoang, M. P. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.06.018 · Cited by 119
Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 117
Roesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 123
Master protocol trials in oncology: Review and new trial designs
Hirakawa, A., Asano, J., Sato, H., & Teramukai, S. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.009 · Cited by 120
Recent advances in the understanding of Langerhans cell histiocytosis
Badalian‐Very, G., Vergilio, J., Degar, B. A., Galindo, C. R., & Rollins, B. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08915.x · Cited by 115
Li, W., & Melton, D. W. (2011) · Oncogene · doi:10.1038/onc.2011.426 · Cited by 116
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Goetz, E. M., Ghandi, M., Treacy, D. J., Wagle, N., & Garraway, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2073 · Cited by 123
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 118
Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Meric‐Bernstam, F., Frampton, G. M., Ferrer-Lozano, J., Yelensky, R., Fidalgo, J. A. P., Wang, Y., Palmer, G. A., Ross, J. S., Miller, V. A., Su, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0482 · Cited by 116
Emerging Role of mTOR in the Response to Cancer Therapeutics
Ilagan, E., & Manning, B. D. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.03.008 · Cited by 118
Svedman, F. C., Pillas, D., Kaur, M., Linder, R., Hansson, J., & Taylor, A. (2016) · Clinical Epidemiology · doi:10.2147/clep.s99021 · Cited by 116
Montor, W. R., Salas, A. R. O. S. E., & de Melo, F. H. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0792-2 · Cited by 118
Desai, J., Gan, H. K., Barrow, C., Jameson, M. B., Atkinson, V. G., Haydon, A. M., Millward, M., Begbie, S. D., Brown, M. P., Markman, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02654 · Cited by 117
Vemurafenib in Melanoma with BRAF V600E Mutation
Dalle, S., Poulalhon, N., & Thomas, L. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1108651 · Cited by 116
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
Self-citationUpdates on histiocytic disorders
Vaiselbuh, S. R., Bryceson, Y. T., Allen, C. E., Whitlock, J. A., & Abla, O. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25017 · Cited by 115
Trial Watch: Peptide-based anticancer vaccines
Pol, J. G., Bloy, N., Buqué, A., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974411 · Cited by 121
Self-citationLabgaa, I., Villacorta-Martín, C., D’Avola, D., Craig, A. J., von Felden, J., Martins-Filho, S. N., Sia, D., Stueck, A., Ward, S. C., Fiel, M. I., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0206-3 · Cited by 117
Updates of reactive oxygen species in melanoma etiology and progression
Liu, F., Dellinger, R. W., & Meyskens, F. L. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.04.007 · Cited by 119
Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
Self-citationTumor Type-Dependent Function of the Par3 Polarity Protein in Skin Tumorigenesis
Iden, S., van Riel, W. E., Schäfer, R., Song, J., Hirose, T., Ohno, S., & Collard, J. G. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.004 · Cited by 115
BRAF inhibitor activity in V600R metastatic melanoma
Klein, O., Clements, A., Menzies, A. M., O'Toole, S. A., Kefford, R. F., & Long, G. V. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.004 · Cited by 114
Biomarkers in Pancreatic Cancer
Fong, Z. V., & Winter, J. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31827654ea · Cited by 116
Targeted agents for cancer treatment during pregnancy
Lambertini, M., Peccatori, F. A., & Azim, H. A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.001 · Cited by 114
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma
Kim, S. Y., Kim, S., Hahn, H. J., Lee, Y. W., Choe, Y. B., & Ahn, K. J. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1113 · Cited by 113
Wong, S. Q., Raleigh, J., Callahan, J., Vergara, I. A., Ftouni, S., Hatzimihalis, A., Colebatch, A. J., Li, J., Semple, T. J., Doig, K., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00009 · Cited by 115
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
Puszkiel, A., Noé, G., Bellesœur, A., Kramkimel, N., Paludetto, M., Thomas‐Schoemann, A., Vidal, M., Goldwasser, F., Chatelut, É., & Blanchet, B. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0703-0 · Cited by 117
Pan-cancer analysis of whole genomesPreprint
Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O., & Stein, L. D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/162784 · Cited by 117
Joseph, R. W., Sullivan, R. J., Harrell, R. K., Stemke‐Hale, K., Panka, D. J., Manoukian, G. E., Percy, A., Bassett, R. L., Ng, C. S., Radvanyi, L. G., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182372636 · Cited by 113
Tumor control versus adverse events with targeted anticancer therapies
Keefe, D. M. K., & Bateman, E. H. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.192 · Cited by 113
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 113
Modeling Melanoma In Vitro and In Vivo
Beaumont, K. A., Mohana‐Kumaran, N., & Haass, N. K. (2013) · Healthcare · doi:10.3390/healthcare2010027 · Cited by 112
Flaherty, L. E., Othus, M. K. D., Atkins, M. B., Tuthill, R. J., Thompson, J. A., Vetto, J. T., Haluska, F. G., Pappo, A. S., Sosman, J. A., Redman, B. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1590 · Cited by 114
Self-citationNardi, V., Sadow, P. M., Juric, D., Zhao, S. D., Cosper, A. K., Bergethon, K. E., Scialabba, V. L., Batten, J. M., Borger, D. R., Iafrate, A. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1842 · Cited by 113
Self-citationTowards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 116
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 114
Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 114
NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells
Jan, Y. J., Chen, J., Zhu, Y., Lu, Y., Chen, S. H., Chung, H., Smalley, M. D., Huang, Y.-W., Dong, J., Chen, L.-C., et al. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.006 · Cited by 115
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
Bevelacqua, V., Bevelacqua, Y., Candido, S., Skarmoutsou, E., Amoroso, A., Guarneri, C., Strazzanti, A., Gangemi, P., Mazzarino, M. C., D’Amico, F., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.594 · Cited by 114
Haroche, J., Arnaud, L., Aubart, F. C., Hervier, B., Charlotte, F., Emile, J., & Amoura, Z. (2013) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2013.02.011 · Cited by 112
BRAF inhibitors in cancer therapy
Johansson, C. H., & Brage, S. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.011 · Cited by 113
Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers
Božić, I., & Nowak, M. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412075111 · Cited by 114
Vemurafenib Induces Senescence Features in Melanoma Cells
Haferkamp, S., Borst, A., Adam, C., Becker, T. M., Motschenbacher, S., Windhövel, S., Hufnagel, A., Houben, R., & Meierjohann, S. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.6 · Cited by 116
Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells
Chartrain, M., Riond, J., Stennevin, A., Vandenberghe, I., Gomes, B., Lamant, L., Meyer, N., Gairin, J. E., Guilbaud, N., & Annereau, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036762 · Cited by 118
Targeted therapies: how personal should we go?
Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 112
Building a Personalized Medicine Infrastructure at a Major Cancer Center
Meric‐Bernstam, F., Farhangfar, C. J., Mendelsohn, J. M., & Mills, G. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3043 · Cited by 112
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z. Z., Chakraborty, A. K., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 114
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 120
Hu, C., & Dignam, J. J. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00086 · Cited by 115
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
Fanelli, G. N., Pozzo, C. A. D., Depetris, I., Schirripa, M., Brignola, S., Biason, P., Balistreri, M., Santo, L. D., Lonardi, S., Munari, G., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1117-2 · Cited by 110
Ugurel, S., Röhmel, J., Ascierto, P. A., Becker, J. C., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.021 · Cited by 114
Self-citationOcular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Choe, C. H., McArthur, G. A., Caro, I., Kempen, J. H., & Amaravadi, R. K. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.003 · Cited by 113
Self-citationEvolving Approaches to Patients with Advanced Differentiated Thyroid Cancer
Haugen, B. R., & Sherman, S. I. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1038 · Cited by 114
Okaniwa, M., Hirose, M., Arita, T., Yabuki, M., Nakamura, A., Takagi, T., Kawamoto, T., Uchiyama, N., Sumita, A., Tsutsumi, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400778d · Cited by 112
Beyond BRAF: where next for melanoma therapy?
Fedorenko, I. V., Gibney, G. T., Sondak, V. K., & Smalley, K. S. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.476 · Cited by 117
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 116
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
Johnson, D. B., Saranga‐Perry, V., Lavin, P., Burnette, W. B., Clark, S. W., Uskavitch, D., Wallace, D. E., Dickson, M. A., Kudchadkar, R. R., & Sosman, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1683 · Cited by 111
Self-citationLi, W., Yu, Y., Wang, H.-L., Yan, A.-H., & Jiang, X.-J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1750-7 · Cited by 82
Functional exploration of colorectal cancer genomes using Drosophila
Bangi, E., Murgia, C., Teague, A., Sansom, O. J., & Cagan, R. L. (2016) · Nature Communications · doi:10.1038/ncomms13615 · Cited by 114
MicroRNAs in melanoma development and resistance to target therapy
Fattore, L., Costantini, S., Malpicci, D., Ruggiero, C. F., Ascierto, P. A., Croce, C. M., Mancini, R., & Ciliberto, G. (2017) · Oncotarget · doi:10.18632/oncotarget.14763 · Cited by 115
Self-citationAllen, C. E., Laetsch, T. W., Mody, R. J., Irwin, M. S., Lim, M. S., Adamson, P. C., Seibel, N. L., Parsons, D. W., Cho, Y., & Janeway, K. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw274 · Cited by 115
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T. S., Seo, C., Merlino, G. T., & Yu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0205-4 · Cited by 115
Kerins, M. J., Milligan, J., Wohlschlegel, J. A., & Ooi, A. (2018) · Cancer Science · doi:10.1111/cas.13701 · Cited by 111
Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 114
Transcriptomics and solid tumors: The next frontier in precision cancer medicine
Tsimberidou, A. M., Fountzilas, E., Bleris, L. G., & Kurzrock, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.007 · Cited by 118
Agarwala, S. S., Eggermont, A. M. M., O'Day, S. J., & Zager, J. S. (2013) · Cancer · doi:10.1002/cncr.28480 · Cited by 112
Self-citationMcCourt, C., McArt, D. G., Mills, K., Catherwood, M. A., Maxwell, P., Waugh, D. J. J., Hamilton, P., O’Sullivan, J. M., & Salto‐Tellez, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069604 · Cited by 111
Corrie, P. G., Marshall, A., Dunn, J., Middleton, M. R., Nathan, P., Gore, M. E., Davidson, N. G. P., Nicholson, S., Kelly, C. G., Marples, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70110-x · Cited by 108
Self-citationChemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors
Klaeger, S., Gohlke, B.-O., Perrin, J., Gupta, V., Heinzlmeir, S., Helm, D., Qiao, H., Bergamini, G., Handa, H., Savitski, M. M., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01063 · Cited by 111
Metadata
- Authors
- Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., & McArthur, G. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Royal Marsden Hospital (GB)
- University of Zurich (CH)
- University of Tübingen (DE)
- European Institute of Oncology (IT)
- Tumour Institute of Tuscany (IT)
- University Health Network (CA)
- University of Manchester (GB)
- Hôpital Saint-André (FR)
- Essen University Hospital (DE)
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- Vanderbilt University (US)
- University of Pittsburgh (US)
- Plexxikon (United States) (US)
- Genentech (US)
- Massachusetts General Hospital (US)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Chapman, Paul B.
- Hauschild, Axel
- Robert, Caroline
- Haanen, John B.
- Ascierto, Paolo
- Larkin, James
- Dummer, Reinhard
- Garbe, Claus
- Testori, Alessandro
- Maio, Michele
- Hogg, David
- Lorigan, Paul
- Jouary, Thomas
- Schadendorf, Dirk
- Ribas, Antoni
- O'Day, Steven J.
- Sosman, Jeffrey A.
- Kirkwood, John M.
- Eggermont, Alexander M.M.
- Li, Jiang
- Hou, Jeannie
- Lee, Richard J.
- Flaherty, Keith T.
- McArthur, Grant A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2507-2516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549296
- OpenAlex
- W2128542677
- Cited by
- 7,720
- References
- 28
- Citations by year
- 2026: 141 · 2025: 187 · 2024: 265 · 2023: 276 · 2022: 401 · 2021: 377 · 2020: 423 · 2019: 470 · 2018: 496 · 2017: 613 · 2016: 660 · 2015: 829 · 2014: 844 · 2013: 865 · 2012: 693
- FWCI
- 332.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (K24CA097588)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, dacarbazine, metastatic melanoma, BRAF V600E mutation, BRAF inhibitors, overall survival, progression-free survival, drug toxicity, keratoacanthoma, photosensitivity
- MeSH terms
- Vemurafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Sulfonamides, Survival Analysis, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
